Eli Lilly and Company (NYSE:LLY) Trading Down 2.3% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) was down 2.3% during trading on Monday . The stock traded as low as $1,109.15 and last traded at $1,122.3230. Approximately 2,910,874 shares traded hands during trading, a decline of 7% from the average daily volume of 3,114,943 shares. The stock had previously closed at $1,148.84.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to investigational KRAS G12C inhibitor olomorasib for previously treated patients with advanced pancreatic cancer. The designation could accelerate regulatory interactions and strengthen Lilly’s oncology pipeline, although the drug remains unapproved and clinical success is not guaranteed. Lilly’s olomorasib receives FDA Breakthrough Therapy designation
• Positive Sentiment: Investors expect Mounjaro and Zepbound to remain the primary growth engines in the second quarter, with market attention focused on prescription demand, revenue growth and early sales trends for newer products. Prior results showed revenue rising more than 55% year over year, supporting the bullish earnings case. Will Mounjaro and Zepbound drive Lilly’s Q2 results?
• Positive Sentiment: Recent analyst targets remain well above the current trading level, with a reported median target of $1,336 and targets as high as $1,500. Healthcare-sector rotation and continued demand for obesity treatments are also supporting the longer-term bullish narrative. Eli Lilly opinions on upcoming earnings
• Neutral Sentiment: Options-market commentary suggests Lilly could experience an unusually large valuation swing following earnings, making the report a major near-term catalyst.
• Negative Sentiment: Valuation is a key concern after the stock’s roughly 300% five-year gain and trillion-dollar-plus market capitalization. A discounted-cash-flow analysis indicates the shares may be below estimated intrinsic value, increasing the risk of profit-taking if earnings or guidance disappoint. Eli Lilly stock valuation analysis
• Negative Sentiment: Competition in obesity medicines is intensifying as Novo Nordisk attempts to regain momentum, while pricing pressure remains an external risk. Separately, one Lilly executive sold 2,500 shares, and several large institutions reduced holdings, adding modestly cautious signals.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Berenberg Bank increased their price objective on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. Barclays raised their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Morgan Stanley upped their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Trading Down 2.3%

The stock’s fifty day simple moving average is $1,152.66 and its 200-day simple moving average is $1,043.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market cap of $1.06 trillion, a PE ratio of 39.87, a PEG ratio of 1.43 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 34.91 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LLY. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $12,976,634,000. J. Stern & Co. LLP boosted its stake in shares of Eli Lilly and Company by 46,191.3% in the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after buying an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. grew its holdings in Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Fifth Third Bancorp raised its position in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after acquiring an additional 1,497,423 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after acquiring an additional 1,432,069 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.